2024
SIOG2024-3-P-065 Relative dose intensity and survival among older adults with advanced gastrointestinal cancers receiving first line chemotherapy
Mohamed M, Rich D, Lund J, Seplaki C, Jensen-Battaglia M, Java J, Culakova E, Ramsdale E, Burnette B, Onitilo A, Mohile S. SIOG2024-3-P-065 Relative dose intensity and survival among older adults with advanced gastrointestinal cancers receiving first line chemotherapy. Journal Of Geriatric Oncology 2024, 15: 101927. DOI: 10.1016/j.jgo.2024.101927.Peer-Reviewed Original ResearchOmission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.
Peng C, Saffo S, Oberstein P, Shusterman M, Thomas C, Becker D, Berlin J, Leichman L, Boursi B, Nagar A, Yu S. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal Of The National Comprehensive Cancer Network 2024, 22: 521-527. PMID: 39236754, DOI: 10.6004/jnccn.2024.7029.Peer-Reviewed Original ResearchMultidrug regimensFOLFIRINOX regimensAdvanced colorectalGastrointestinal cancerAssociated with decreased survivalGranulocyte colony-stimulating factorCompare survival outcomesGastrointestinal cancer treatmentBaseline clinical factorsKaplan-Meier analysisFirst-line FOLFOXMulticenter cohort studyColony-stimulating factorInverse probability of treatmentAdvanced gastrointestinal cancerTreatment selection biasProbability of treatmentHealth care savingsCox proportional hazardsOverall survivalEffective regimenIPTW analysisSurvival outcomesPancreatic cancerAssociated with reductionsUnveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.Peer-Reviewed Original ResearchMetastatic colorectal cancerMetastatic gastric cancerMetastatic gastric cancer patientsPeritoneal metastasisMalignant ascitesAdvanced gastrointestinal cancerSurvival outcomesMedian peritoneal cancer index scoreGastrointestinal cancerPeritoneal cancer index scoreGastric cancerMetastatic colorectal cancer patientsSubgroup of patientsMedian OSProgression-FreeOverall survivalSystemic therapyPrognostic significancePatient survivalAscites groupPoor outcomeRetrospective analysisColorectal cancerRandomized trialsAscites
2003
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clinical Cancer Research 2003, 9: 6052-61. PMID: 14676132.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisCaspase 3CaspasesCell DivisionColonic NeoplasmsCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent KinasesCyclinsCytochromes cEnzyme ActivationEnzyme InhibitorsFlavonoidsGamma RaysMaleMiceMice, NudeMicroscopy, FluorescencePiperidinesPoly(ADP-ribose) PolymerasesStomach NeoplasmsTransplantation, HeterologousTumor Cells, CulturedConceptsEffect of flavopiridolHCT-116 cellsMKN-74Single agentInduction of apoptosisParental HCT-116 cellsAdvanced gastrointestinal cancerTumor-bearing animalsCyclin-dependent kinase inhibitor flavopiridolEfficacy of combinationNational Cancer InstituteMKN-74 cellsGastric cancer cellsP21 protein expressionKinase inhibitor flavopiridolAdjuvant treatmentCyclin-dependent kinase inhibitorLoss of p21HCT-116Gastrointestinal cancerTumor regressionCancer cell line HCT-116Human colon cancer cell line HCT-116Gastric cancerCancer Institute
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply